Natera Inc. and NSTX Inc. owe Ravgen Inc. $57 million for infringing a patent dealing with genetic testing methods using cell-free DNA, a Texas federal jury determined.
Jurrors returned the verdict Tuesday in the US District Court for the Western District of Texas after a trial that opened Jan. 8 in Austin, according to both parties in the case. The jury heard closing arguments Jan. 12.
Ravgen also won a multimillion-dollar verdict in September 2022 against Laboratory Corporation of America Holdings for infringing the same patent by creating a prenatal test.
Ravgen sued Natera and its subsidiary NSTX in June ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.